1. Puneeth G, Mahesh S, Adithya H, Bhargava JS, Kumari HAC, Gururaj H, et al. Analysis of drug classification using mechanism of action. J Phys Conf Ser 2021; 1914: 012034.
2. Swinney D, Anthony J. Mechanisms of successful drug action. FASEB J 2010; 24: 527.
3. Ryall RW. Mechanisms of drug action on the nervous system. 2nd ed. Cambridge: Cambridge University Press; 1989.
4. Porter CC. Chemical mechanisms of drug action. Ann Intern Med 1970; 74: 309-315.
5. Zhao J, Wang A, Su F, Chen Y, Feng H. Construction of knowledge graph of drug-action mechanism. In: 2021 3rd Int Conf Adv Comput Technol Inf Sci Commun (CTISC); 2021. p. 166-171.
6. Gururaj HL, Flammini F, Kumari HAC, Puneeth G, Kumar BRS. Classification of drugs based on mechanism of action using machine learning techniques. Discover Artif Intell 2021; 1: 1-14.
7. Gourley D. Basic mechanisms of drug action. Fortschr Arzneimittelforsch Prog Drug Res 1964; 7: 11-57.
8. Brody T. Mechanism of action of diseases and drugs—Part I. In: Mechanisms of Action of Drugs and Diseases. 2016. p. 569-594.
9. Brody T. Mechanism of Action, Part I. Clin Trials 2012; 471-491.
10. Van den Heuvel TW, Cohen A, Rissmann R. European drug market entries 2015 with new mechanisms of action. Clin Med 2016; 16: 475-480.
11. Alessandro L, Niccolo P, Filippo Z, Lucien K, Dal Peraro F, Matteo. Mechanism of action (MoA) prediction - kaggle competition. Kaggle Competitions. 2020.
12. Cirinciani M, Da Pozzo E, Trincavelli ML, Milazzo P, Martini C. Drug mechanism: A bioinformatic update. Biochem Pharmacol 2024; 228: 116078.
13. Palko N, Potemkin V, Grishina M. Decision tree for mechanism of antitumor drugs action prediction. Bull South Ural State Univ Chem 2019; 10: 102-110.
14. Ismail MK. A study of the mechanism on preventive action towards family members from involved in drug addiction. Taman Pelangi Ledang J Malay Med Assoc 2011.
15. Bishnoi M. Pharmacodynamics: Drug mechanisms of action. Pharma Innov J 2019; 8: 25494.
16. Ghidini M, Silva SG, Evangelista J, do Vale ML, Farooqi A, Pinheiro M. Nanomedicine for the delivery of RNA in cancer. Cancers 2022; 14: 2677.
17. Guo P, Haque F. RNA Nanotechnology and Therapeutics. In: Methods in Molecular Biology. 2013. p. 109-120.
18. Shukla G, Haque F, Tor Y, Wilhelmsson LM, Toulmé J, Isambert H, et al. A boost for the emerging field of RNA nanotechnology. ACS Nano 2011; 5: 3405-3418.
19. Huang X, Kong N, Zhang X, Cao Y, Langer R, Tao W. The landscape of mRNA nanomedicine. Nat Med 2022; 28: 2273-2287.
20. Rhym LH, Anderson DG. Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art. Med 2022; 3: 167-187.
21. Barros SA, Gollob J. Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev 2012; 64: 1730-1737.
22. Bhatia P, Vasaikar S, Wali A. A landscape of nanomedicine innovations in India. Nanotechnol Rev 2018; 7: 131-148.
23. Chandler M, Johnson B, Khisamutdinov EF, Dobrovolskaia M, Sztuba-Solinska J, Salem A, et al. The international society of RNA nanotechnology and nanomedicine (ISRNN): The present and future of the burgeoning field. ACS Nano 2021; 15: 16957-16973.
24. Haque F, Guo P. Overview of methods in RNA nanotechnology: Synthesis, purification, and characterization of RNA nanoparticles. Methods Mol Biol 2015; 1297: 1-19.
25. Zhang H, Pi F, Shu D, Vieweger M, Guo P. Using RNA nanoparticles with thermostable motifs and fluorogenic modules for real-time detection of RNA folding and turnover in prokaryotic and eukaryotic cells. Methods Mol Biol 2015; 1297: 95-111.
26. Zhang Y-X, Yan H, Wei Z, Hong H, Huang D, Liu G, et al. NanoMUD: Profiling of pseudouridine and N1-methylpseudouridine using Oxford Nanopore direct RNA sequencing. Int J Biol Macromol 2024; 270: 132433.
27. Tursi NJ, Xu Z, Kulp DW, Weiner D. Gene-encoded nanoparticle vaccine platforms for in vivo assembly of multimeric antigen to promote adaptive immunity. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2023; 15: e1880.
28. Nalwa H. A special issue on reviews in nanomedicine, drug delivery and vaccine development. J Biomed Nanotechnol 2014; 10: 1635-1640.
29. Beg S, Almalki W, Khatoon F, Alharbi KS, Alghamdi S, Akhter MH, et al. Lipid- and polymer-based nanocomplexes in nucleic acid delivery as cancer vaccines. Drug Discov Today 2021; 26: 1891-1903.
30. Mufamadi MS, Ngoepe M, Nobela O, Maluleke N, Phorah B, Methula B, et al. Next-generation vaccines: Nanovaccines in the fight against SARS-CoV-2 virus and beyond SARS-CoV-2. BioMed Res Int. 2023; 2023: 4588659.
31. Pozharov V, Minko T. Nanotechnology-based RNA vaccines: Fundamentals, advantages and challenges. Pharmaceutics 2023; 15: 194.
32. Taha MM, Abdelwahab S, Moni SS, Farasani A, Aljahdali IA, Oraibi B, et al. Nano-enhanced immunity: A bibliometric analysis of nanoparticles in vaccine adjuvant research. Hum Vaccin Immunother 2024; 20: 2427464.
33. Cai JM, Wang H, Wang D, Li Y. Improving cancer vaccine efficiency by nanomedicine. Adv Biosyst 2019; 3: e1800287.
34. Zhu X, Radovic-Moreno A, Wu J, Langer R, Shi J. Nanomedicine in the management of microbial infection - overview and perspectives. Nano Today 2014; 9: 478-498.
35. Fangueiro J, Severino P, Souto S, Souto E. Nanomedicines for Immunization and Vaccines. In: Nanomedicine for Drug Delivery. 2012. p. 435-450.
36. Tenchov R, Bird R, Curtze A, Zhou Q. Lipid nanoparticles-From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 2021; 15: 16982-17015.
37. Milane L, Amiji M. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: Impact on translational nanomedicine. Drug Deliv Transl Res 2021; 11: 1309-1315.
38. Milane L, Amiji M. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Deliv Transl Res 2021; 11: 1309-1315.
39. Cai Y. Nanoparticle based nucleic acid vaccines. 2024; 12924: 1292418-6.
40. Guerrini G, Magrì D, Gioria S, Medaglini D, Calzolai L. Characterization of nanoparticles-based vaccines for COVID-19. Nat Nanotechnol 2022; 17: 570-576.
41. Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada. CNW 2019.
42. Hoy SM. Patisiran: First global approval. Drugs. 2018; 78: 1625-1631.
43. Rizk M, Tüzmen S. Patisiran for the treatment of patients with familial amyloid polyneuropathy. Drugs Today 2019; 55: 315-327.
44. Hu B, Weng Y, Xia X-h, Liang X, Huang Y. Clinical advances of siRNA therapeutics. J Gene Med 2019; 21: e3097.
45. Weng Y, Xiao H, Zhang J, Liang X, Huang Y. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv 2019; 37: 801-825.
46. Suzuki Y, Ishihara H. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. Drug Metab Pharmacokinet. 2021; 41: 100424.
47. U.S. Food and Drug Administration. Approval package for Onpattro (patisiran) lipid complex injection. Silver Spring, MD: FDA; 2018.
48. Bartoszewski R, Sikorski A. Editorial focus: Understanding off-target effects as the key to successful RNAi therapy. Cell Mol Biol Lett 2019; 24: 69.
49. Yonezawa S, Koide H, Asai T. Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Adv Drug Deliv Rev 2020; 154: 64-78.
50. Dong Y, Siegwart D, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev 2019; 144: 133-147.
51. Kuznetsova S, Oretskaya TS. Nanoparticulate delivery systems for targeted delivery of nucleic acids to cells. Nanotechnol Russia 2010; 5: 583-600.
52. Sharma A, Gupta L, Gupta U. Nanoparticles as nucleic acid delivery vectors. In: Nanotechnology and Nanomedicine. 2017.p. 13-42.
53. Coelho T, Adams D, Silva A, Lozeron P, Hawkins P, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013; 369: 819-829.
54. Rizk M, Tüzmen S. Update on the clinical utility of an RNA interference-based treatment: Focus on Patisiran. Pharmacogenomics Pers Med 2017; 10: 267-278.
55. Yamashita T, Ueda M, Koike H, Sekijima Y, Yoshinaga T, Kodaira M, et al. Patisiran, an RNAi therapeutic for patients with hereditary transthyretin‐mediated amyloidosis: Sub‐analysis in Japanese patients from the APOLLO study. Neurol Clin Neurosci 2020; 8: 251-260.
56. Butler JS, Chan A, Costelha S, Fishman S, Willoughby J, Borland T, et al. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid 2016; 23: 109-118.
57. Gillmore J, Falk R, Maurer M, Hanna M, Karsten V, Vest J, et al. Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis. Orphanet J Rare Dis 2015; 10: O2.
58. Pushkarev AV, Nikitin M. Gene and small molecule delivery in vivo using novel nanoparticle-based systems. 2022 Int Conf Laser Optics (ICLO) 2022.p. 1-1.
59. Li Z, Su Y, Zhang H. The applications of gold nanoparticles in drug delivery. In: Proceedings of SPIE. 2022; 12179: 121790Y.
60. Rathore KS, Patel S, Pujara N. Nanoparticulate drug delivery system. Saarbrucken: LAP Lambert Academic Publishing; 2013.
61. Ping Q. Nanoparticulate systems for drug delivery. Chin J New Drugs 2002; 1: 42-46.
62. Penumarthi A, Basak P, Smooker P, Shukla R. Hitching a ride: Enhancing nucleic acid delivery into target cells through nanoparticles. In: Nucleic Acid Delivery. 2020. p. 373-457.
63. Afarani HT, Stretz H. Usage of nanoparticles for drug delivery in cancer therapy. J Drug Deliv 2017; 1: 1.
64. Chen D, Liu XW, Lu X, Tian JW. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Front Pharmacol 2023; 14: 1111991.
65. Hallaj-Nezhadi S, Lotfipour F, Dass C. Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy. Die Pharmazie 2010; 65: 855-859.
66. Gonçalves P, Martins H, Costelha S, Maia L, Saraiva M. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Amyloid 2016; 23: 249-253.
67. Adams D, Cauquil C, Labeyrie C, Beaudonnet G, Algalarrondo V, Théaudin M. TTR kinetic stabilizers and TTR gene silencing: A new era in therapy for familial amyloidotic polyneuropathies. Expert Opin Pharmacother 2016; 17: 791-802.
68. Kurosawa T, Igarashi S, Nishizawa M, Onodera O. Selective silencing of a mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun 2005; 337: 1012-1018.
69. Gonçalves N, Gonçalves P, Ventosa M, Coelho A, Saraiva M. Tissue remodeling after RNAi-mediated knockdown of TTR in a familial amyloidotic polyneuropathy mouse model. Orphanet J Rare Dis 2015; 10: P5.
70. Thassu D, Deleers M, Pathak Y. Nanoparticulate drug delivery systems: An overview. In: Nanoparticles in Medicine. 2007.
71. Rashmi C, Nesalin JAJ, Mani TT. Nanoparticulate drug delivery system-review. Int J Res Pharm Chem 2016; 6: 491-500.
72. Saber N, Senti ME, Schiffelers R. Lipid nanoparticles for nucleic acid delivery beyond the liver. Hum Gene Ther 2024; 26: 106.
73. Williams EC, Alcantar NA, Wiranowska M. Nanoparticle-based delivery of therapeutics to glioma. In: Wiranowska M, Vrionis FD, editors. Gliomas: Symptoms, Diagnosis and Treatment
Options. New York: Nova Science Publishers; 2013. p. 371-395.
74. Buddolla AL, Kim S. Recent insights into the development of nucleic acid-based nanoparticles for tumor-targeted drug delivery. Colloids Surf B Biointerfaces 2018; 172: 315-322.
75. Lin J-T, Liu Z, Zhu Q, Rong X, Liang C-L, Wang J, et al. Redox-responsive nanocarriers for drug and gene co-delivery based on chitosan derivatives modified mesoporous silica nanoparticles. Colloids Surf B Biointerfaces 2017; 155: 41-50.
76. Kong S, Gao X, Wang Q, Lin J, Qiu L, Xie M. Two birds with one stone: A novel dithiomaleimide-based GalNAc-siRNA conjugate enabling good siRNA delivery and traceability. Molecules 2023; 28: 7184.
77. Liu X, Li Y, Liu X, Huang Y, Wang F, Li J, et al. GalNAc end-capped poly (β-amino ester)s with screened side chains for efficient gene delivery. Small Methods 2025; 9: e2401286.
78. Lu J, Dai Y, He Y, Zhang T, Zhang J, Chen X, et al. Organ/cell-selective intracellular delivery of biologics via N-acetylated galactosamine-functionalized polydisulfide conjugates. J Am Chem Soc 2024; 146: 3974-3983.
79. Li Q, Dong M, Chen P. Novel diamine-scaffold based N-acetylgalactosamine (GalNAc)–siRNA conjugate: Synthesis and in vivo activities. RSC Adv 2024; 14: 17461–17466.
80. Naghib SM, Ahmadi B, Mikaeeli Kangarshahi B, Mozafari MR. Chitosan-based smart stimuli-responsive nanoparticles for gene delivery and gene therapy: Recent progresses on cancer therapy. Int J Biol Macromol 2024; 278: 134542.
81. Zhao Y, Vivero-Escoto JL, Slowing I, Trewyn BT, Lin VS. Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery. Expert Opin Drug Deliv 2010; 7: 1013-1029.
82. Zou T, Lu W, Mezhuev Y, Lan M, Li L, Liu F, et al. A review of nanoparticle drug delivery systems responsive to endogenous breast cancer microenvironment. Eur J Pharm Biopharm 2021; 118: 107-118.
83. Zhang Q, Kuang G, Li W, Wang J, Ren H, Zhao Y. Stimuli-responsive gene delivery nanocarriers for cancer therapy. Nano-Micro Lett 2023; 15: 111.
84. Seelam ML, Yarraguntla SR, Paravastu VKK, Vurukuti SS, Mylavarapu SSV. Polymeric nanoparticles with stimuli-responsive properties for drug delivery. GSC Biol Pharm Sci 2022; 20: 259-268.
85. Sharma AK, Gupta L, Gupta U. Nanoparticles as nucleic acid delivery vectors. In: Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids. Amsterdam: Elsevier; 2017. p. 13-42.
86. Miller AD. Towards safe nanoparticle technologies for nucleic acid therapeutics. Tumori J 2008; 94: 234-245.
87. Rehman S, Nabi B, Pottoo F, Baboota S, Ali J. Nanoparticle based gene therapy approach: A pioneering rebellion in the management of psychiatric disorders. Curr Gene Ther 2020; 20: 92-103.
88. Moku G. Polymeric nanoparticles for cancer gene therapy. Biomed J Sci Tech Res 2021; 34: 27546–27550.
89. Wei X, Wei Y. Opportunities and challenges in the nanoparticles for nucleic acid therapeutics: the first approval of an RNAi nanoparticle for treatment of a rare disease. Natl Sci Rev 2019; 6: 1105–1106.
90. Chen F, Liu Q, Xiong Y, Xu L. Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route. Front Pharmacol 2022; 13: 984981.
91. Le Breton A, Préat V, Féron O. Design and development of polymeric nanoparticles for targeted delivery of nucleic acid-based therapeutics to tumor sites. Drug Discov Today 2010; 15: 842-850.
92. Mukalel AJ, Riley RS, Zhang R, Mitchell MJ. Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy. Cancer Lett 2019; 458: 102-112.
93. Gao Y, Liu X, Chen N, Yang X, Tang F. Recent advance of liposome nanoparticles for nucleic acid therapy. Pharmaceutics 2023; 15: 178.
94. Wu F, Qiu F, Wai-Keong SA, Diao Y. The smart dual-stimuli responsive nanoparticles for controlled anti-tumor drug release and cancer therapy. Anti-Cancer Agents Med Chem 2020; 20: 1479-1495.
95. Rescignano N, Kenny JM. Stimuli-responsive core-shell nanoparticles. In: Core-Shell Nanostructures for Drug Delivery and Theranostics. Amsterdam: Elsevier;2018. p. 245-258.
96. Cheng R, Meng F, Deng C, Klok H, Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 2013; 34: 3647-3657.
97. Li Y, Gao G, Lee DS. Stimulus-sensitive polymeric nanoparticles and their applications as drug and gene carriers. Adv Healthcare Mater 2013; 2: 1-22.
98. Bhattacharya S, Prajapati BG, Singh S. A critical review on the dissemination of pH and stimuli-responsive polymeric nanoparticular systems to improve drug delivery in cancer therapy. Crit Rev Oncol Hematol 2023; 185: 103961.
99. Smith HA. Regulatory considerations for nucleic acid vaccines. Vaccine 1994; 12: 1515–1519.
100. Naeem S, Zhang J, Zhang Y, Wang Y. Nucleic acid therapeutics: Past, present, and future. Mol Ther Nucleic Acids 2024; 36: 102440.
101. Husain S.R, Han J, Au P, Shannon K, Puri R. Gene therapy for cancer: Regulatory considerations for approval. Cancer Gene Ther 2015; 22: 554-563.
102. Halioua-Haubold C-L, Peyer J.G, Smith J.A, Arshad Z, Scholz M, Brindley D, et al. Regulatory considerations for gene therapy products in the US, EU, and Japan. Yale J Biol Med 2017; 90: 683-693.
103. Kondo A, Ribeiro A. Regulatory considerations for cellular therapy. J Bone Marrow Transplant Cell Ther 2022; 3: 166-171.
104. Hunter P. Advanced therapies push regulatory boundaries. EMBO Rep 2017; 18: 209-212.
105. Plaut R.D, Stibitz S. Regulatory considerations for bacteriophage therapy products. In: Harper D.R, Abedon S.T, Burrowes B.H, McConville M.L, eds. Phage Therapy: A Practical Approach. Cham: Springer; 2019: 327-341.
)